Arnaud Denis, a French actor and theatre director known for his productions of Les Liaisons dangereuses and Les Femmes savantes, died by euthanasia in Belgium on Tuesday at the age of 43. His lawyer, Philippe Courtois, confirmed the news to AFP, stating that Denis's decision was made after consultations with three doctors in Namur.
Denis had been in unbearable pain since a polypropylene mesh implant was fitted in July 2023 to treat a right groin hernia. The operation led to a cascade of complications, including chronic pain and immune system disruption. In April 2024, he travelled to the United States to have the implant removed, but his condition did not improve.
He was later diagnosed with myalgic encephalomyelitis, in the context of ASIA syndrome—an inflammatory reaction linked to exposure to an adjuvant. The implant is believed to have triggered persistent inflammation and disrupted his immune system.
In an interview with the regional daily Dauphiné Libéré in early 2026, Denis described his suffering: "I can no longer leave my home, I have no social life, I have no life at all. I no longer have anything that constitutes the dignity of a man's life. And it is getting worse and worse. I live like a cancer patient in the terminal phase. The doctors have nothing left to offer me."
A legal battle and a collective
In January 2026, Denis filed a complaint with the Public Health Division of the Paris public prosecutor's office for "unintentional injuries," but the case was dropped at the end of August for lack of sufficiently established offence. His lawyer condemned what he called "a silent public health scandal," arguing that thousands of patients are "exposed to high-risk implants, without clear information or informed consent, suffering serious medical complications, most of them irreversible."
Denis had also set up a collective called "French victims of hernia prostheses," which gathered hundreds of testimonies on social media from people who suffered adverse effects linked to anti-hernia implants. The group has become a focal point for patients across France and beyond, highlighting a growing concern about medical device safety in Europe.
Courtois pointed to a letter from Medtronic, the manufacturer of the Dextile device, acknowledging that implanting parietal reinforcement devices may cause chronic and acute post-operative pain. However, he noted that this information is included in instructions intended for healthcare professionals, not for patients, who receive no such warning.
Denis's case has reignited debates about medical device regulation and patient informed consent across the European Union. While the EU has a centralised system for high-risk medical devices, critics argue that post-market surveillance and transparency remain inadequate. The case also highlights the divergent approaches to euthanasia among member states: Belgium, along with the Netherlands and Luxembourg, permits it under strict conditions, while France and many other countries do not.
Denis's decision to end his life in Belgium underscores the cross-border dimension of end-of-life care in Europe. For many patients in countries where euthanasia is illegal, travelling to Belgium or the Netherlands has become a last resort. This has led to calls for a broader European debate on the issue, though national sensitivities remain strong.
In a statement before his death, Denis said: "A man knows deep down inside when he is doomed." On 18 March, he was admitted to a palliative care unit in a Belgian hospital, pending approval of his euthanasia request. His death has been met with an outpouring of grief and anger from his supporters, who see it as a tragic consequence of medical negligence.
The case also draws attention to the broader issue of medical implants and their potential long-term risks. Similar concerns have been raised about breast implants, hip replacements, and other devices. European health authorities have been urged to strengthen oversight and ensure that patients are fully informed before undergoing such procedures.
As Europe grapples with these challenges, the story of Arnaud Denis serves as a stark reminder of the human cost when medical regulation falls short. His legacy, through the collective he founded, may help push for change in how medical devices are tested, approved, and monitored across the continent.
